MPLN has always been on the forefront of laboratory medicine and inspired the genesis of women's health testing using liquid cytology and molecular diagnostics. As a result of MPLN's significant involvement in STI-related clinical trials, MPLN has access to the latest advances in technology and automation, and shares these innovations with our pathology clients. MLPN continually updates clinical diagnostic testing platforms and assays to enable us to focus on better patient outcomes and reducing cost.
MPLN now offers the Hologic GenProbe APTIMA® HPV 16 18/45 Genotype Assay, which identifies the two most highly oncogenic and persistent high-risk HPV types known to cause high-grade cervical neoplasia. The assay also facilitiates risk-stratification of patients at greater risk for cervical disease in order to tailor care more appropriately.
Women's health tests available from MPLN on ThinPrep® PAP and SurePathTM Test Pack liquid cytology media include: HPV High Risk, HPV 16 14/45 Genotype, Chlamydia trachomatis, Neisseria gonorrhoea, Herpes simplex and Trichomonas vaginalis.
Hubbard R.A (2003) Human Papillomavirus Testing Methods. Arch Pathol Lab Med 127:940-945
Seabrook J, Hubbard R.A, (2003) Achieving quality reproducible results and maintaining compliance in molecular diagnostic testing of human papillomavirus. Arch Pathol Lab Med. 127:978-83.